



## Research Article

## Storage stability and performance of aqueous and dry formulations of *Helicoverpa armigera* nuclear polyhedrosis virus

P. N. MANE\*, M. P. MOHARIL<sup>1</sup>, N. S. SATPUTE<sup>2</sup>, S. M. THAKARE<sup>2</sup>, G. K. Giri<sup>3</sup>, SWAPNIL GAIKWAD<sup>4</sup>, A. K. GADE<sup>4</sup> and M. K. RAI<sup>4</sup>

Oilseeds Research Unit, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Krishinagar, Akola - 444 104, Maharashtra, India.

<sup>1</sup>Biotechnology Centre, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Krishinagar, Akola - 444 104, Maharashtra, India.

<sup>2</sup>Department of Entomology, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Krishinagar, Akola - 444 104, Maharashtra, India.

<sup>3</sup>Department of Plant Pathology, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Krishinagar, Akola - 444 104, Maharashtra, India.

<sup>4</sup>Department of Biotechnology, Sant Gadgebaba University, Amravati, Maharashtra, India

\*Corresponding author E-mail: pnmane\_ento@rediffmail.com

**ABSTRACT:** Experiment on storage stability and performance of aqueous and dry formulation of *Helicoverpa armigera* nuclear polyhedrosis virus (*HaNPV*) was conducted during 2011-2013 in Bio control laboratory, Department of Entomology and Insect Biotechnology laboratory, Biotechnology Centre, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Akola with an objective to develop potent *HaNPV* formulation for improving shelf life and performance. Aqueous and dry form of *HaNPV* formulations with antimicrobials, UV protectant and phagostimulant were prepared and studied their shelf life and performance during storage. Synthesized and characterized the Silver nanoparticles. Prepared fresh *Ha NPV* required for preparing different formulation. The contaminants associated, storage stability and larvicidal activity of formulated *HaNPV* was studied. Data revealed that, *HaNPV* formulations having Silver nanoparticles @ 8 µl/ml of *HaNPV* and 80 µl/ml of *HaNPV* checked the bacterial contamination up to 13 months of the storage period, did not affect the viability of POBs and insecticidal properties of *HaNPV* formulation. Aqueous form of *HaNPV* + Streptomycin @ 0.18 g/lit of *HaNPV* + Tinopal 1% + Sucrose 1% , dry form of *HaNPV* + Streptomycin @ 0.18 g/lit of *HaNPV* + Tinopal 1% + Sucrose 1% and *HaNPV* + Streptomycin @ 0.18 g/lit of *HaNPV* + sucrose remain stabled up to 12 months. However, aqueous form of *HaNPV* alone reduces the insecticidal properties from the 9th month of storage period. While, dry form of *HaNPV* alone reduces the insecticidal properties from the 12th month of storage period. From the result, it was noticed that dry form of *HaNPV* formulation having antimicrobial found more stable than aqueous form.

**KEY WORDS:** Shelf life, storage stability, *HaNPV* formulation, silver nano particles

(Article chronicle: Received: 04-02-2016 Revised: 25-02-2016 Accepted: 05-03-2016)

### INTRODUCTION

*Helicoverpa armigera* nuclear polyhedrosis virus is the potential agent for the biological control of *Helicoverpa armigera* (Hubner) (Lepidoptera: Noctuidae) because of their high pathogenicity, narrow host range, and safety to vertebrates, plants and the environment. Other advantages of baculovirus for pest control include lack of toxic residues and unlikelihood development of stable resistance. Despite these advantages, their practical application as microbial pesticides has not been fully exploited. Among the various limiting factors, microbial contamination during storage period is an important one that affects the physical stability and insecticidal properties (Podgwaite *et al.*, 1983; Grzywacz *et al.*, 1997). The aqueous preparations can undergo bacterial fermentation and loss of activ-

ity when stored at room temperature (Cherry *et al.*, 2000). Semi-purified product has secondary microbial contamination. In respect of liquid suspensions, water have mainly been used as carriers, although the growth of contaminating microorganisms in water based concentrates has made water an inferior carrier, (Jones and Burge 1997). Viruses can remain highly viable for several years, especially those with intact inclusion bodies stored in insect cadaver, dry powder or in suspension (Jacques, 1985). Additives can be used to inhibit microbial contamination as well as protect baculoviruses from adverse environmental factors, which enhance storage stability and maximize application efficiency (Lasa *et al.*, 2008). The formulation of a microbial agent can be improved by adding ingredients which increase the stability and shelf-life of the product (Jones and Burge, 1997). Keeping all this in view, an attempt was

made to develop *HaNPV* formulation in aqueous and dry form for improving shelf life and performance.

**MATERIALS AND METHODS**

The present investigation was carried out at Department of Entomology and Biotechnology Centre, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Akola during the year 2011 to 2013 in Completely Randomized Block Design, replicated thrice. Silver nanoparticles (SNPs) were synthesized as per the procedure followed by Monali Gajbhiye *et al.*, (2013). Synthesized SNPs were detected by reading UV-Vis spectra and were further characterized by Nanoparticle Tracking Analysis System, Zeta measurement and Transmission Electron Microscopy. *HaNPV* required for its formulation (Aqueous and Dry) was prepared freshly. Aqueous formulations were prepared by adding the required quantity of adjuvants in the desired concentration of *HaNPV*. Dry formulations were prepared by direct impregnation of required quantity of adjuvants with typical full grown virus infected larvae and dried it by using lyophilizer. For evaluation of dry formulations, the formulation was milled and suspended in sufficient quantity of distilled water so as to meet the desired concentration of *HaNPV*. For stability study, the formulations were stored at room temperature and assessed for microbial contaminants asso-

ciated with both aqueous and dry formulations at monthly interval using procedure followed by Lasa *et al.* (2008). The viability of formulations was assessed by counting POBs at three month intervals as per the procedure followed by Gupta *et al.* (2009). The larvicidal activity was tested at three month intervals against second instars larvae of *H. armigera*. For larvicidal study, 50 µl of *HaNPV* formulation was smeared on half broken soaked chickpea grain and thirty laboratory reared larvae were released in each treatment. Larvae were starved for 24 hours before release. Fresh prepared water soaked chickpea was used for further feeding. Mortality caused at ten days after treatment was recorded and analyzed by using ANOVA.

**RESULTS AND DISCUSSION**

**Bacterial contaminants associated with *HaNPV* formulations**

Pooled mean data given in Table 1, revealed that *HaNPV* formulation having silver nanoparticles @ 8 µl/ml of *HaNPV* and 80 µl/ml of *HaNPV* checked the bacterial contamination up to 13 months of the storage period. Aqueous form of *HaNPV* + Streptomycin @ 0.18 g/lit of *HaNPV* + Tinopal 1% + Sucrose 1%, dry form of *HaNPV* + Streptomycin @ 0.18 g/lit of *HaNPV* + Tinopal 1% + Sucrose 1% and *HaNPV* + Streptomycin @ 0.18 g/lit of

**Table 1. Bacterial contamination associated with *HaNPV* formulation during storage (Pooled mean)**

S.N	Treatments	CFU/ml of <i>HaNPV</i> at												
		1 <sup>st</sup> M	2 <sup>nd</sup> M	3 <sup>rd</sup> M	4 <sup>th</sup> M	5 <sup>th</sup> M	6 <sup>th</sup> M	7 <sup>th</sup> M	8 <sup>th</sup> M	9 <sup>th</sup> M	10 <sup>th</sup> M	11 <sup>th</sup> M	12 <sup>th</sup> M	13 <sup>th</sup> M
Aqueous <i>HaNPV</i> formulation														
1	<i>HaNPV</i> + Silver nanoparticles @ 8 µl/ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
2	<i>HaNPV</i> +Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13
3	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
4	<i>HaNPV</i> Alone	1.29 x10 <sup>7</sup>	1.38 x10 <sup>7</sup>	1.42 x10 <sup>7</sup>	1.28 x10 <sup>7</sup>	1.35 x10 <sup>7</sup>	1.45 x10 <sup>7</sup>	1.75 x10 <sup>7</sup>	1.9 x10 <sup>8</sup>	3.2 x10 <sup>8</sup>	3.6 x10 <sup>8</sup>	12.0 x10 <sup>7</sup>	13.0 x10 <sup>7</sup>	15.0 x10 <sup>7</sup>
Lyophilized <i>HaNPV</i> formulation														
5	<i>HaNPV</i> + Silver nanoparticles @ 8µl / ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6	<i>HaNPV</i> + Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11
7	<i>HaNPV</i> + Silver nanoparticles @ 8 µl/ ml of <i>HaNPV</i> + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8	<i>HaNPV</i> + Streptomycin @ .18g/lit of <i>HaNPV</i> + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10
9	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10	<i>HaNPV</i> Alone	0.83 x10 <sup>7</sup>	1.13 x10 <sup>7</sup>	1.16 x10 <sup>7</sup>	1.17 x10 <sup>7</sup>	1.18 x10 <sup>7</sup>	1.23 x10 <sup>7</sup>	1.27 x10 <sup>7</sup>	1.33 x10 <sup>7</sup>	1.43 x10 <sup>7</sup>	2.12 x10 <sup>7</sup>	2.25 x10 <sup>7</sup>	2.35 x10 <sup>7</sup>	7.7 x10 <sup>7</sup>

\*M =Month

*HaNPV* + sucrose inhibited the bacterial contamination up to 12 months of storage period and recorded  $0.13 \times 10^7$ ,  $0.11 \times 10^7$  and  $0.10 \times 10^7$  CFU/ml of *HaNPV* formulation, respectively. The bacterial count of *HaNPV* alone in aqueous form was  $1.29 \times 10^7$  CFU/ml and remains stable up to 8 months of storage period. In 9<sup>th</sup> and 10<sup>th</sup> months the count was  $3.2 \times 10^7$  and  $3.6 \times 10^7$  CFU/ml, respectively. During 11<sup>th</sup>, 12<sup>th</sup> and 13<sup>th</sup> months, the bacterial count was  $12.0 \times 10^7$ ,  $13.0 \times 10^7$  and  $15.0 \times 10^7$  CFU/ml, respectively. Initial bacterial count in dry form of *HaNPV* alone was  $0.83 \times 10^7$  and almost it was stable up to the 12 months of storage period and in the 13<sup>th</sup> month of storage the count was  $7.7 \times 10^7$  CFU/ml.

### Viability of POBs

*HaNPV* formulation having antimicrobials *i.e.* silver nanoparticles @ 8 µl/ml of *HaNPV* and 80 µl/ml of *HaNPV* and streptomycin @ 0.18 g/lit of *HaNPV* did not affect the POBs. POBs of aqueous form of *HaNPV* alone remains viable up to 6 months of storage period and from 9<sup>th</sup> month onward it was reduced. POBs of dry form of *HaNPV* alone remains viable up to 11 months of storage period and it was reduced in 12<sup>th</sup> month (Table 2).

Reduction in POBs over 1<sup>st</sup> month were calculated and given in Table 3. From the data, it was observed that 20.70, 42.00 and 53.37 per cent reduction in POBs was found

during 6<sup>th</sup>, 9<sup>th</sup> and 12<sup>th</sup> month, respectively, from aqueous form of *HaNPV*. Dry form of *HaNPV* recorded 12.61 and 25.07 per cent reduction in POBs during 9<sup>th</sup> and 12<sup>th</sup> month of storage period, respectively. Similar observations were made by Lasa *et al.* (2008), mentioned that concentration of OBs fell by 30 per cent after 6 months of storage and it remained unchanged for the remaining 12 months of the study. OB formulation with bacteriostatic or antioxidant additives, together with storage, will likely result in a *SeM-NPV* biopesticide shelf life that exceeds 18 months.

### Larvicidal activity of *HaNPV* formulations

Data given in Table 4 revealed that aqueous and dry form of *HaNPV* formulations having silver nanoparticles and streptomycin did not influence the insecticidal properties of *HaNPV* formulation over storage period. However, aqueous form of *HaNPV* reduces the insecticidal properties from the 9<sup>th</sup> month of storage period. While, dry form of *HaNPV* reduces the insecticidal properties from the 12<sup>th</sup> month of storage period.

Overall results perceived that dry form of *HaNPV* formulations found more stable than aqueous form. Grant Michelle (2008) noted that decrease in the insecticidal activity of NPV suspensions could be due to several factors including microbial load from the natural flora of the insects. The free water content in unformulated suspensions

**Table 2. Viability of POBs of *HaNPV* formulation during storage. (Pooled mean of Set I and Set II)**

S.N	Treatments	POBs/ml of <i>HaNPV</i> at				
		1 <sup>st</sup> Month	3 <sup>rd</sup> Month	6 <sup>th</sup> Month	9 <sup>th</sup> Month	12 <sup>th</sup> Month
Aqueous <i>HaNPV</i> formulation						
1	<i>HaNPV</i> + Silver nanoparticles @ 8 µl /ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	$1.405 \times 10^9$	$1.422 \times 10^9$	$1.377 \times 10^9$	$1.313 \times 10^9$	$1.320 \times 10^9$
2	<i>HaNPV</i> +Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	$1.331 \times 10^9$	$1.331 \times 10^9$	$1.295 \times 10^9$	$1.296 \times 10^9$	$1.265 \times 10^9$
3	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	$1.310 \times 10^9$	$1.310 \times 10^9$	$1.297 \times 10^9$	$1.262 \times 10^9$	$1.260 \times 10^9$
4	<i>HaNPV</i> Alone	$1.319 \times 10^9$	$1.319 \times 10^9$	$1.046 \times 10^9$	$0.765 \times 10^9$	$0.615 \times 10^9$
Lyophilized <i>HaNPV</i> formulation						
5	<i>HaNPV</i> + Silver nanoparticles @ 8µl / ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	$5.683 \times 10^9$	$5.658 \times 10^9$	$5.675 \times 10^9$	$5.450 \times 10^9$	$5.500 \times 10^9$
6	<i>HaNPV</i> + Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	$5.817 \times 10^9$	$5.817 \times 10^9$	$5.625 \times 10^9$	$5.558 \times 10^9$	$5.521 \times 10^9$
7	<i>HaNPV</i> + Silver nanoparticles @ 8 µl/ ml of <i>HaNPV</i> + Sucrose 1%	$5.125 \times 10^9$	$5.125 \times 10^9$	$5.258 \times 10^9$	$5.233 \times 10^9$	$5.329 \times 10^9$
8	<i>HaNPV</i> + Streptomycin @ .18g/lit of <i>HaNPV</i> + Sucrose 1%	$5.725 \times 10^9$	$5.725 \times 10^9$	$5.417 \times 10^9$	$5.267 \times 10^9$	$5.160 \times 10^9$
9	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	$5.817 \times 10^9$	$5.825 \times 10^9$	$5.892 \times 10^9$	$5.642 \times 10^9$	$5.639 \times 10^9$
10	<i>HaNPV</i> Alone	$4.758 \times 10^9$	$4.758 \times 10^9$	$4.608 \times 10^9$	$4.158 \times 10^9$	$3.565 \times 10^9$

**Table 3. Reduction in POBs of *HaNPV* formulation during storage period**

S.N	Treatments	% reduction in POBs				
		1 <sup>st</sup> month	3 <sup>rd</sup> month	6 <sup>th</sup> month	9 <sup>th</sup> month	12 <sup>th</sup> month
Aqueous <i>HaNPV</i> formulation						
1	<i>HaNPV</i> + Silver nanoparticles @ 8 µl /ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.0	0.00	1.99	2.49	2.63
2	<i>HaNPV</i> +Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.0	0.00	2.70	2.63	4.96
3	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	0.0	0.00	0.99	3.66	3.82
4	<i>HaNPV</i> Alone	0.0	0.00	20.70	42.00	53.37
Lyophilized <i>HaNPV</i> formulation						
5	<i>HaNPV</i> + Silver nanoparticles @ 8µl / ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.0	0.44	0.14	4.10	3.22
6	<i>HaNPV</i> + Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	0.0	0.00	3.30	4.45	5.09
7	<i>HaNPV</i> + Silver nanoparticles @ 8 µl/ ml of <i>HaNPV</i> + Sucrose 1%	0.0	0.00	0.00	0.00	0.00
8	<i>HaNPV</i> + Streptomycin @ .18g/lit of <i>HaNPV</i> + Sucrose 1%	0.0	0.00	5.38	8.00	9.87
9	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	0.0	0.00	0.00	3.01	3.06
10	<i>HaNPV</i> Alone	0.0	0.00	3.15	12.61	25.07

**Table 4. Influence of storage period on the larvicidal activity of *HaNPV* formulation**

S.N	Treatments	% larval mortality at 10 DAT (Pooled)				
		1 <sup>st</sup> Month	3 <sup>rd</sup> Month	6 <sup>th</sup> Month	9 <sup>th</sup> Month	12 <sup>th</sup> Month
Aqueous <i>HaNPV</i> formulation						
1	<i>HaNPV</i> + Silver nanoparticles @ 8 µl /ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	88.77 (70.31)	88.89 (70.57)	87.78 (69.58)	88.33 (70.06)	88.89 (70.57)
2	<i>HaNPV</i> +Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	87.08 (68.87)	86.67 (68.68)	85.56 (67.69)	85.56 (67.69)	87.78 (69.58)
3	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	82.58 (65.22)	82.22 (65.08)	82.22 (65.08)	83.89 (66.38)	85.00 (67.23)
4	<i>HaNPV</i> Alone	81.47 (64.36)	82.22 (65.08)	82.22 (65.08)	68.33 (55.76)	56.67 (48.87)
Lyophilized <i>HaNPV</i> formulation						
5	<i>HaNPV</i> + Silver nanoparticles @ 8µl / ml of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	87.22 (69.12)	88.89 (70.57)	87.22 (69.12)	87.78 (69.58)	87.78 (69.58)
6	<i>HaNPV</i> + Streptomycin @ 0.18 g/lit of <i>HaNPV</i> + Tinopal 1% + Sucrose 1%	85.56 (67.69)	87.78 (69.58)	85.56 (67.69)	85.56 (67.69)	85.56 (67.69)
7	<i>HaNPV</i> + Silver nanoparticles @ 8 µl/ ml of <i>HaNPV</i> + Sucrose 1%	84.44 (66.80)	85.56 (67.69)	84.44 (66.80)	85.56 (67.69)	85.56 (67.69)
8	<i>HaNPV</i> + Streptomycin @ .18g/lit of <i>HaNPV</i> + Sucrose 1%	84.44 (66.80)	84.44 (66.80)	84.44 (66.80)	84.44 (66.80)	84.44 (66.80)
9	<i>HaNPV</i> + Silver nanoparticles @ 80 µl/ml of <i>HaNPV</i> + Sucrose 1%	82.22 (65.08)	82.22 (65.08)	82.22 (65.08)	82.22 (65.08)	82.22 (65.08)
10	<i>HaNPV</i> Alone	82.22 (65.08)	82.22 (65.08)	82.22 (65.08)	82.22 (65.08)	70.56 (57.14)
F Test		Sig	Sig	Sig	Sig	Sig
S.Em.±		0.82	0.95	0.88	0.86	1.08
C.D (P= 5 %)		2.39	2.79	2.58	2.53	3.16
C.V. %		2.33	2.68	2.51	2.49	3.15

may be higher. Microorganisms rely on a water activity and this could be the reason for higher microbial load in unformulated suspensions.

Present study of intervention of Nano technology for stability of *HaNPV* is an innovative attempt, the literature is not traceable. However, some scientists studied the storage stability of different NPV formulation by using different additives. Freeze drying of NPV was known to reduce bacterial concentration. The aqueous preparations of NPV can undergo bacterial fermentation and loss of activity when stored at room temperature. The stability of dried virus and of virus stored in oil has been shown to improve longevity in storage but lacking in consistent improvement (Cherry *et al.*, 2000). Patricia *et al.* (2002) concurred that the potency of virus was not affected in the production process of freeze drying virus, but a 50 % loss of insecticidal activity was observed after storage. Patrick and Wood (1995) worked on stabilization and infectivity of baculovirus preoccluded virions. The ability to produce large amount of high-potency viral preparations in larvae and the convenience of being able to lyophilize the preparations for long-term storage showed promise for the use of preoccluded virus preparations as bio-pesticides. Retention of some quantity of larval debris in the formulation may enhance the activity of the virus on host plants. However care should be taken to insure that a semi-purified product does not have secondary microbial contaminations (Mehrvar *et al.*, 2007). Arthurs *et al.* (2006) demonstrated the extended persistence of *CpGV* with spray dried formulation. However, the shelf life was found to be reduced. This reduction in shelf life of spray dried NPV formulation has also been cited as an issue affecting the successive commercialization.

Present results showed that silver nanoparticles could be the most promising additive for a *HaNPV* in terms of the attributes evaluated. Silver nanoparticles are potent and broad-spectrum antimicrobial agents. The mode of their antibacterial action against *Escherichia coli* was investigated, and proved to be an efficient physicochemical system conferring antimicrobial activities (Chun-Nam Lok *et al.*, 2006). Silver nanoparticles also expressed significant UV-protection capability (Vigneshwaran *et al.*, 2007).

#### ACKNOWLEDGEMENT

Authors are thankful to The Head, Department of Entomology and Incharge, Biotechnology Centre, Dr. Panjabrao Deshmukh Krishi Vidyapeeth, Akola for providing the facilities for carried out the research work.

#### REFERENCES

- Arthurs AS, Lacey LA, Bhele RW. 2006. Evaluation of spray-dried lignin based formulations and adjuvants as solar protectants for the granulovirus of the codling moth, *Cydia pomonella* I(L). *J Invertebr Pathol.* **93**: 88–95.
- Cherry AJ, Rabindra RJ, Parnell M, Geetha AN, Kennedy JS, Grzywacz D. 2000. Field evaluation of *Helicoverpa armigera* nucleopolyhedrovirus formulations for control of the chickpea pod-borer, *H. armigera* (Hubn.), on chickpea (*Cicer arietinum* var. Shoba) in southern India. *Crop Prot.* **19**: 51–60.
- Lok C-N, Ho C-M, Chen R, He Q-Y, Yu W-Y, Sun H, Tam PK-H, Chiu J-F, Che C-M. 2006. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. *J Proteome Res.* **5**(4): 916–924.
- Michelle G. 2008. *The development and evaluation of Baculovirus formulations for the biological control of the African cotton bollworm*. MSc Thesis. Faculty of Science, University of Witwatersrand, Johannesburg.
- Grzywacz D, McKinley D, Jones KA, Moawad G. 1997. Microbial contamination of *Spodoptera littoralis* nuclear polyhedrosis virus produced in insects in Egypt. *J Invertebr Pathol.* **69**: 151–156.
- Gupta RK, Raina RK, Arora RK, Bali K. 2007. Selection and field effectiveness of Nucleopolyhedrosis isolates against *Helicoverpa armigera* (Hubner). *I J Virol.* **3**(2): 45–59.
- Jacques RP. 1985. Stability of entomopathogenic viruses in the environment, pp. 285–360. In: Maramorosch K, Sherman KE. (Eds.). *Viral insecticides for biological control*. New York, Academic Press.
- Jones KA, Burge H. 1997. Product stability: from experimental preparation to commercial reality. *BCPC Symposium Proceedings.* **68**: 163–171.
- Lasa R, Williams T, Caballero P. 2008. Insecticidal properties and microbial contaminants in a *Spodoptera exigua* multiple nucleopolyhedrovirus (Baculoviridae) formulation stored at different temperatures. *J Economic Entomol.* **101**(1): 42–49.
- Mehrvar A, Rabindra RJ, Veenakumari K, Narabanchi GB. 2007. Susceptibility of crude and semi-purified extracts of nucleopolyhedrovirus isolates of

- Helicoverpa armigera* (Hubner) to simulated sunlight. *J Biol Control* **21**(1): 91–96.
- Gajbhiye M, Kesharwani J, Ingale A, Gade A, Rai M. 2009. Fungus-mediated synthesis of silver nanoparticles and their activity against pathogenic fungi in combination with fluconazole. *Nanomedicine: nanotechnology. Biol Medicine*. **5**: 382–386.
- Patrick RH, Wood HA. 1995. *In Vivo* production, stabilization, and infectivity of baculovirus preoccluded virions. *Appl Environ Microbiol*. **62**(1): 105–108.
- Patricia TG, McGuire MR, Behle RW, Shasha BS, Pinge RL. 2002. Storage stability of *Anagrapha falcifera* nucleopolyhedrosis virus in spray dried formulations. *J Invertebr Pathol*. **79**: 7–16.
- Podgwaite JD, Bruen RB, Shapiro M. 1983. Microorganisms associated with production lots of the nuclear polyhedrosis virus of the Gypsy moth *Lymantria dispar*. *Entomophaga* **28**: 9–16.
- Vigneshwaran N, Kathe AA, Varadarajan PV, Nachane RO, Balsubramanya RH. 2007. Functional finishing of cotton fabrics using silver nanoparticles. *J Nanosci Nanotechnol*. **7**(6): 1893–1897.